AKR1C3 conversion of DHEA-S remaining in patients after leuprolide, Abi, and potentially Enz therapy may feed intratumoral steroidogenesis to replenish AR ligands within prostate cancer cells and contribute to ARSI drug resistance. Here, AR is linked to Familial prostate cancer.